Celltrion, Inc. Logo

Celltrion, Inc.

A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celltrion, Inc. is a leading global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapeutics. A pioneer in the biosimilar field, Celltrion launched the world's first monoclonal antibody biosimilar and continues to be a market leader. The company's portfolio includes a range of biosimilars and novel drugs targeting therapeutic areas such as immunology, oncology, hematology, and endocrinology. Celltrion provides comprehensive, end-to-end solutions across the biopharmaceutical value chain, from R&D and clinical trials to production and sales, with a commitment to improving worldwide patient access to high-quality, affordable medicines.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Celltrion, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 724.1 KB
2025-09-17 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 33.3 KB
2025-09-08 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획보고서
Korean 70.7 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.0 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-09-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part2))
Korean 12.2 KB
2025-09-01 00:00
Major Shareholding Notification
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 31.0 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
JEIL PHARMACEUTICAL CO.,LTD Logo
Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.
South Korea 271980
JEIL PHARMA HOLDINGS INC. Logo
Develops and distributes APIs, generics, and modified drugs, specializing in injections.
South Korea 002620
JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea 216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea 007370
JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea 234080
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea 067290
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan 4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan 4521
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.